iiinova — where your digital self keeps evolving

cdr-life.bsky.social @cdr-life.bsky.social · 15/10/2026

CDR-Life is heading to #ESMO26 in Madrid, Oct. 23–27! CEO Christian Leisner, CMO Dimitrios Chondros, MD, and colleagues look forward to discussing progress across our T cell engager pipeline, including CDR404 and CDR609. Attending? Reach out to schedule a meeting!

000

cdr-life.bsky.social @cdr-life.bsky.social · 13/10/2026

A look back at the 26th Annual Biotech in Europe Forum in Basel! CDR-Life CFO Konstantin von Schulthess joined an immunology and inflammation investor panel, while CBO Sarah Holland chaired a pharma strategy and dealmaking discussion with industry leaders. Thanks to all who participated!

000

cdr-life.bsky.social @cdr-life.bsky.social · 08/10/2026

CBO Sarah Holland co-chaired a panel on Pharma-Biotech Partnering in Emerging Technology Platforms at the 1st Annual Healthcare Impact Summit. Sarah joined leaders from Roche, AstraZeneca, NucleoTech, Merck KGaA, GSK and Wellington Partners to discuss partnering around emerging technologies.

000

cdr-life.bsky.social @cdr-life.bsky.social · 16/09/2026

CDR-Life will be at the Biotech in Europe Forum in Basel, Oct. 7–8. CFO Konstantin von Schulthess will join a panel on immunology & inflammation, and CBO Sarah Holland will chair the Pharma Strategy & Dealmaking Panel. #CDRLife

010

cdr-life.bsky.social @cdr-life.bsky.social · 09/09/2026

Today we announced CDR209, a novel T cell engager for axial spondyloarthritis (axSpA), where significant unmet need remains. Built on our M-gager® platform, CDR209 is designed to target disease-driving TRBV9+ T cells while preserving broader immune function. bit.ly/4xKOHj3

012

cdr-life.bsky.social @cdr-life.bsky.social · 04/09/2026

We recently welcomed PhD students and postdoctoral researchers from the Life Science Zurich Young Scientist Network to CDR-Life to talk about careers beyond academia, working in biotech and the many paths into industry. Thanks to everyone who joined us for a great discussion!

010

cdr-life.bsky.social @cdr-life.bsky.social · 31/08/2026

CDR-Life is heading to #SITC EU in Lausanne, Sept. 3–4. Leonardo Borras, Dimitrios Chondros, MD, and Melissa Vrohlings will be there to connect and discuss our M-gager platform and highly selective T cell engagers for solid tumors. Reach out to meet the team!

000

cdr-life.bsky.social @cdr-life.bsky.social · 19/08/2026

Boston bound! CDR-Life CEO Christian Leisner will attend the Wells Fargo Healthcare Conference, Sept. 8–10. We look forward to connecting with investors and sharing the latest progress across our M-gager® platform and T cell engager pipeline.#WellsFargoHealthcare

010

cdr-life.bsky.social @cdr-life.bsky.social · 07/08/2026

Thank you to the Global Entrepreneurial Leadership Program for inviting our Chief Business Officer, @Sarah Holland, to speak with this year's cohort. The discussion explored branding, building momentum and knowing when to scale as a growing biotech company. Great discussion!

010

cdr-life.bsky.social @cdr-life.bsky.social · 10/07/2026

The "Life" in CDR-Life isn't only about the patients we hope to impact. It's also about the people behind our science. Last week, our team came together for our annual summer outing. Strong science starts with strong collaboration. #LifeAtCDRLife

000

cdr-life.bsky.social @cdr-life.bsky.social · 09/06/2026

Heading to #BIO2026? CDR-Life CBO Sarah Holland will be in San Diego June 22–25 to discuss progress across our M-gager® platform, including CDR404, CDR609 and our expanding autoimmune pipeline. Attending BIO? We'd love to connect.

010

cdr-life.bsky.social @cdr-life.bsky.social · 01/06/2026

ASCO is off to a great start. The CDR-Life team is enjoying valuable discussions around next-generation T cell engagers, our Phase 1/2 study of CDR404, and the potential of our M-gager® platform to expand the reach of immunotherapy. If you're attending #ASCO2026, we'd love to connect

000

cdr-life.bsky.social @cdr-life.bsky.social · 21/05/2026

CDR-Life and our first-in-class LGR5-targeted M-gager® T cell engager CDR609 featured in BioCentury’s overview of the emerging LGR5 landscape. AACR 2026 data showed encouraging activity in CRC models, including MSS and KRAS mutant tumors. @biocentury.bsky.social www.biocentury.com/article/6595...

biocentury.com

The small but diverse LGR5 pipeline

Phase III results from Genmab’s first-in-class petosemtamab in head and neck cancer are expected next half, but the bispecific’s LGR5 target ...

000

cdr-life.bsky.social @cdr-life.bsky.social · 20/05/2026

CDR-Life CEO Christian Leisner will attend the Jefferies Global Healthcare Conference in New York next month to discuss progress across our M-gager® platform, including CDR404, CDR609 and our autoimmune collaboration with Boehringer Ingelheim. #JefferiesHealthcare

000

cdr-life.bsky.social @cdr-life.bsky.social · 19/05/2026

Heading to #ASCO2026! CDR404 is in Phase 1/2 testing for MAGE-A4+ solid tumors, with first-in-human data showing key T cell engager hallmarks. We are also advancing CDR609, our LGR5-targeted T cell engager for solid tumors. Meet the CDR-Life team in Chicago!

000

cdr-life.bsky.social @cdr-life.bsky.social · 11/05/2026

Improving lives is part of our mission, including the wellbeing of our own teams. That’s why many colleagues are cycling this May and June as part of the #biketowork initiative. More movement, shared motivation, sustainable commutes! 🚴

000

cdr-life.bsky.social @cdr-life.bsky.social · 05/05/2026

Welcome to CDR-Life, Norbu Bargeman, our new scientific intern from the University of Zurich! Outside the lab, Norbu enjoys nature, time with friends, and is a youth leader with Jungwacht Blauring, organizing camps and activities. Glad to have you on board!

010

cdr-life.bsky.social @cdr-life.bsky.social · 22/04/2026

Strong scientific engagement at #AACR2026 around our poster on CDR609 our first in class M-gager® T-cell engager targeting LGR5. Valuable discussions on our preclinical data, including LGR5-expressing solid tumor models and approaches to “cold” tumors.Thanks to all who stopped by and to our team!

000

cdr-life.bsky.social @cdr-life.bsky.social · 09/04/2026

CMO Leena Gandhi joins a CMO Summit 360° panel on evolving collaboration models to advance new therapies. A timely discussion as the industry rethinks how innovation moves forward.

000

cdr-life.bsky.social @cdr-life.bsky.social · 01/04/2026

Great opportunity to join an amazing team! CDR-Life is now hiring a Lab Technician Protein Purification. Learn more: bit.ly/4sbAt6V To apply, please contact: hr@cdr-life.com

000

cdr-life.bsky.social @cdr-life.bsky.social · 23/03/2026

CDR-Life achieves first preclinical milestone in its autoimmune collaboration with @Boehringer Ingelheim, advancing a next-generation antibody-based T cell engager designed for selective B-cell depletion. BI has elected to proceed with further development of the candidate. bit.ly/4sXLh9B

022

cdr-life.bsky.social @cdr-life.bsky.social · 17/03/2026

Athanasia Dasargyri will present new data on CDR609, a first-in-class T cell engager targeting LGR5+ solid tumors, at #AACR2026. Preclinical studies show strong activity across colorectal cancer subtypes and enhanced effects in combination with cetuximab. #TCellEngagers

031

cdr-life.bsky.social @cdr-life.bsky.social · 17/03/2026

Athanasia Dasargyri of CDR-Life will present new data on CDR609, a first-in-class T cell engager targeting LGR5+ solid tumors, at #AACR2026. Preclinical studies show strong activity across colorectal cancer subtypes and enhanced effects in combination with cetuximab. #TCellEngagers

000

cdr-life.bsky.social @cdr-life.bsky.social · 17/03/2026

Chief Business Officer Sarah Holland will be in Lisbon, Portugal for BIO-Europe Spring, discussing how CDR-Life's M-gager® platform is redefining what antibody-based T cell engagers can do for solid tumors and autoimmune diseases. Let’s connect!

011

cdr-life.bsky.social @cdr-life.bsky.social · 12/03/2026

As part of our Women and Girls in Life Sciences festivities, CDR-Life hosted students from Literargymnasium Rämibühl school. Students received a lab tour and learned about working at a biotech company. It was great seeing the next generation of scientists and company leaders!

010

cdr-life.bsky.social @cdr-life.bsky.social · 10/03/2026

Great opportunity to join an amazing team! CDR-Life is hiring a Scientific Intern to gain hands-on experience and contribute to meaningful projects in our fast-moving biotech environment. View the full job description here: www.cdr-life.com/careers/#ope...

110

cdr-life.bsky.social @cdr-life.bsky.social · 09/03/2026

Last week at the Sachs Annual European Life Sciences CEO Forum for Partnering and Investment, CBO Sarah Holland moderated a panel on biotech–pharma dealmaking. Thanks to the panelists for a great discussion!

000

cdr-life.bsky.social @cdr-life.bsky.social · 02/03/2026

Our CBO Sarah Holland will chair the Pharma Dealmakers Roundtable at the Sachs Associates 19th Annual European Life Sciences CEO Forum with esteemed biotech colleagues. #Sachs_ELSF #DealMaking #Biopharma

020

cdr-life.bsky.social @cdr-life.bsky.social · 27/02/2026

Join us at ImmunoMark2026 in London to discuss next-gen precision IO. Biomarker-driven development powers our M-gager® TCE platform. In Phase 1 with CDR404, which is targeting MAGE-A4 in solid tumors, we’re generating translational and PD data to inform dose and patient selection. Let’s connect!

000

cdr-life.bsky.social @cdr-life.bsky.social · 23/02/2026

Welcome Polonca Andermann, PhD, as Head of Clinical Operations at CDR-Life. With 20+ years of global oncology trial leadership, she will oversee execution of our M-gager® T cell engager programs and help advance key clinical milestones. We are thrilled you are part of the team, Polonca!

000

cdr-life.bsky.social @cdr-life.bsky.social · 09/02/2026

In Scrip’s “What Does 2026 Hold for Biopharma?” Christian Leisner, CEO of CDR-Life, explains why T cell engagers are hitting an inflection point— becoming one of immuno-oncology’s most investable modalities. Read more: bit.ly/4tlZPB3

010

cdr-life.bsky.social @cdr-life.bsky.social · 03/02/2026

Dimitrios Chondros, MD, joins the CDR-Life leadership team as Chief Medical Officer. With 20+ years of global oncology and drug development experience, he will lead clinical and translational strategy as we advance our M-gager® platform. Welcome, Dimitrios! Learn more: bit.ly/4qcUPfa

011

cdr-life.bsky.social @cdr-life.bsky.social · 30/01/2026

Sarah Holland, Chief Business Officer of CDR-Life and President of Swiss HLG, will join a British-Swiss Chamber of Commerce Zurich Chapter panel with Herbert Smith Freehills Kramer on navigating today’s complex M&A landscape amid geopolitical and market disruption. Register: lnkd.in/dbC79J2a

000

cdr-life.bsky.social @cdr-life.bsky.social · 19/12/2025

Warm holiday greetings from the CDR-Life team! As we close out a milestone-filled 2025, we’re grateful for the support of our partners and the biotech community. Wishing you a healthy and successful New Year!

010

cdr-life.bsky.social @cdr-life.bsky.social · 12/12/2025

Dr. Matteo Morotti represented CDR-Life in a Citeline roundtable on the future of immuno-oncology, where leaders discussed how bi- and tri-specific antibodies, T-cell engagers and other next-gen modalities are reshaping the landscape. Download! discover.pharmaignite.com/novotech-esm...

discover.pharmaignite.com

Breaking Through the Checkpoint Blockade in Immuno-Oncology

000

cdr-life.bsky.social @cdr-life.bsky.social · 08/12/2025

We’re heading to #JPM2026 to share how our antibody-based M-gager® T cell engagers are opening new paths in solid tumors and autoimmune disease. With emerging first-in-human activity for CDR404 and strong pipeline momentum, we’re excited for the year ahead. Let’s meet!

000

cdr-life.bsky.social @cdr-life.bsky.social · 04/12/2025

We will be at ESMO IO talking about our T cell engager (TCE) platform and CDR404, our novel, bispecific and bivalent antibody-derived TCE that targets MAGE-A4. Don’t miss our Phase 1 poster: #ESMOImmuno25

000

cdr-life.bsky.social @cdr-life.bsky.social · 14/11/2025

For National Future Day, CDR-Life opened its labs to students eager to learn how medicines are discovered and developed. Partnering with Life Science Cares Switzerland ensures that opportunities like this reach children who might otherwise never see science up close. #Zukunftstag

010

cdr-life.bsky.social @cdr-life.bsky.social · 13/11/2025

Chief Business Officer Sarah Holland joins an expert panel at the LSX Informa Investival Showcase, sharing strategies for winning in today’s shifting biopharma and medtech partnering landscape.

011

cdr-life.bsky.social @cdr-life.bsky.social · 04/11/2025

Thrilled to expand our partnership w @boehringerglobal.bsky.social to advance CDR111, a trispecific M-gager® designed for broad B-cell depletion in autoimmune diseases. This validates the reach of our antibody fragment–based T-cell engager platform beyond oncology and retinal health. bit.ly/492ru2m

011

cdr-life.bsky.social @cdr-life.bsky.social · 28/10/2025

CDR-Life’s Sarah Holland joins #BIOEurope in Vienna to discuss our M-gager® platform, advancing potent, precise T cell engagers for solid tumors and autoimmune diseases. Latest: CDR404 clinical data + CDR609 preclinical results. Let’s meet!

011

cdr-life.bsky.social @cdr-life.bsky.social · 27/10/2025

Our team will be in London for #JefferiesHealthcare, sharing how our M-gager® platform is setting a new benchmark for T cell engager precision, unlocking new possibilities in both solid tumors and autoimmune diseases. We welcome the chance to connect!

011

cdr-life.bsky.social @cdr-life.bsky.social · 23/10/2025

Early clinical data from CDR404 show all four hallmarks of T cell engager activity in patients with advanced MAGE-A4+ solid tumors, validating the potency of our M-gager® platform and its ability to reach intracellular targets once thought out of reach for antibody-based therapeutics. bit.ly/47Cj00p

010

cdr-life.bsky.social @cdr-life.bsky.social · 13/10/2025

CDR-Life is at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting! Join us Oct 23, 12:30–4 pm (Poster Session A, Hall D) for posters on our M-gager® TCEs: • CDR404 – MAGE-A4+ solid tumors • CDR609 – First-in-class LGR5-targeted TCE

111

cdr-life.bsky.social @cdr-life.bsky.social · 11/09/2025

Proud to have our CBO Sarah Holland chair the Pharma Strategy & Dealmaking Panel at the #Sachs_BEF alongside leaders from @abbvie.bsky.social, Covington & Burling LLP, GSK, Merck, Novartis and @sobibird.bsky.social

000

cdr-life.bsky.social @cdr-life.bsky.social · 13/08/2025

Aug 25–29: Our CBO Sarah Holland joins Biotechgate Digital Partnering to discuss partnering our T cell engagers for solid tumors & autoimmune diseases, and how our M-gager® platform is advancing a highly specific clinical pipeline. Still spots open—reach out to connect!

000

cdr-life.bsky.social @cdr-life.bsky.social · 04/08/2025

Meet Romina Doerig, Developability Expert at CDR-Life. She’s spent 4 years assessing molecule stability & solubility to help predict success from discovery to clinic. Her motto: take the chance—you’ll regret the ones you don’t. Fun fact: she never visits the same place twice!

011

cdr-life.bsky.social @cdr-life.bsky.social · 26/06/2025

CDR-Life announces CDR609, a novel T-cell engager targeting LGR5—a highly tumor-specific antigen broadly expressed across common solid tumors including colorectal and pancreatic cancer. Built on our M-gager® platform. IND-enabling studies planned for H2 2025. Details: bit.ly/46dO0ne

011

cdr-life.bsky.social @cdr-life.bsky.social · 03/06/2025

CEO Christian Leisner talks targeting “clean” cancer antigens with T-cell engagers, early CDR404 data, expansion into autoimmunity (CDR111), Boehringer deal & why Switzerland is ideal for biotech. Full PharmaBoardroom interview: pharmaboardroom.com/interviews/c...

001

cdr-life.bsky.social @cdr-life.bsky.social · 29/05/2025

Our CEO Christian Leisner will be at the Jefferies Global Healthcare Conference in NYC next week, sharing how our M-gager® platform is redefining T cell engager precision in solid tumors & autoimmune disease. Connect to learn more. #JefferiesHealthcare

030